FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents


Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) Doai > Cyclopeptides > 5 Or 6 Peptide Repeating Units In Known Peptide Chain

5 Or 6 Peptide Repeating Units In Known Peptide Chain

5 Or 6 Peptide Repeating Units In Known Peptide Chain patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

11/04/10 - 20100279941 - Cd36 modulation and uses thereof
Methods, uses, kits and products are described for the prevention and treatment of ischemia-associated cardiopathies such as myocardial ischemia/reperfusion (I/R) injury, based on the selective modulation of CD36....

09/02/10 - 20100222281 - Delivery of hydrophilic drugs
Compositions comprising a lipophilic derivative of a hydrophilic drug and an amphiphile compound for use in therapy of the human or animal body are provided. Methods of medical treatment, wherein a composition according to the invention is administered to a human or animal body also form part of the invention....

08/19/10 - 20100210566 - Azapeptides as cd36 binding compounds
An azapeptide derivative of growth hormone releasing peptide (GHRP) of Formula I: A-(Xaa)a-N(RA)—N(RB)—C(O)-(Xaa′)b-B which binds to CD 36....

08/12/10 - 20100204153 - Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection
The present invention is directed to the use of the peptide compound Tyr-Val-Lys-Arg-Val-Lys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical...

08/12/10 - 20100204154 - Use of the peptide rfmwmr as a therapeutic agent
The present invention is directed to the use of the peptide compound Ac-Arg-Phe-Met-Trp-Met-Arg-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical...

08/12/10 - 20100204155 - Use of the peptide sfllr-oh and muramyl dipeptide as therapeutic agents
The present invention is directed to the use of the peptide compound Ser-Phe-Leu-Leu-Arg-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical...

08/12/10 - 20100204156 - Use of thymopentin as a therapeutic agent
The present invention is directed to the use of the peptide compound Arg-Lys-Asp-Val-Tyr-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical...

08/12/10 - 20100204157 - Use of a peptide as a therapeutic agent
The present invention is directed to the use of the peptide compound Phe-Phe-Val-Ala-Pro as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical...

08/12/10 - 20100204158 - Combination of splenopentin and thymopentin and the use thereof in medicine
The present invention is directed to the use of the combination of the peptide compounds Arg-Lys-Glu-Val-Tyr-OH and Arg-Lys-Asp-Val-Tyr-OH as a therapeutic combination for prophylaxis and/or treatment of cancer, a heart and vascular disease, an infectious disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, or an autoimmune disease....

08/05/10 - 20100197606 - Non-proteolysable oligopeptides that inhibit glycoprotein gp41 of the aids virus
The invention relates to non-proteolysable oligopeptides that inhibit glycoprotein 41 of the AIDS virus. More specifically, the invention relates to the identification of oligopeptides, particularly hexapeptides, (D), (L) or mixed, preferably D-hexapeptides, which inhibit the binding of a retrovirus to a target cell, thereby providing novel therapies against infection from...

08/05/10 - 20100197607 - Mucin hypersecretion inhibitors and methods of use
Peptides are provided that comprise less than 24 amino acids. The peptides have an amino acid sequence selected from the group consisting of: (a) an amino acid sequence having from 4 to 6 contiguous amino acids of a reference sequence PEPTIDE 1; (b) an amino acid sequence substantially identical to...

07/22/10 - 20100184702 - Selective high-affinity polydentate ligands and methods of making such
This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or...

07/22/10 - 20100184703 - Use of peptide derivatives for treating pathologies resulting from ischemia
The inventors have studied the kinetic and hierarchy of activation of apoptogenic caspases during myocardial ischemia and have found that caspase 2 plays a major role during the cardiac pathology by a very fast activation after an ischemic episode. Experiments were carried out on animal models of transitory or permanent...

07/22/10 - 20100184704 - Use of the peptide gly-arg-gly-asp-asn-pro as a therapeutic agent
The present invention is directed to the use of the peptide compound Gly-Arg-Gly-Asp-Asn-Pro-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical...

07/22/10 - 20100184705 - Therapeutic peptides and vaccines
Compositions are disclosed that induce broadly HIV therapeutic and vaccine inducing antibodies against diverse HIV clades and relate to the ability to identify HIV gp120-derived short peptide sequence immunogens and various therapeutic compositions made from the identified peptides which compose CCR5 binding sites. Also disclosed are methods of selecting peptide...

07/08/10 - 20100173851 - Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these...

07/08/10 - 20100173852 - Use of agents that down-regulate expression of tanis and/or p21 waf1/cip1/sd1 genes, and use of agents that inhibit, degrade, sequester or prevent the neurotoxicity of gene product proteins of tanis and p21 waf1/cip1/sd1 genes
The present invention provides compositions and methods for treating glaucoma, ocular hypertension, and age-related macular degeneration. More specifically, the present invention describes the use of agents that down-regulate expression of tanis and/or p21Waf1/Cip1/Sd1 genes to treat such disorders of the eye....

06/24/10 - 20100160241 - Novel compound having gpr54 agonistic activity
R6 is an amino group or an N-alkyl substituted amino group, having a low-molecular weight and a superior GPR54 agonist activity, and a pharmaceutical composition containing the compound....

05/13/10 - 20100120697 - Tumor activated prodrugs
The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1); Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to...

05/06/10 - 20100113369 - Means for preventing and treating cellular death and their biological applications
Inhibitors for preventing, blacking/silencing caspase-2 activity in cell death....

04/22/10 - 20100099629 - Ophthalmological composition
An object is to find the minimum activity expression site of fibronectin, clarify the actions of this minimum unit in relation to opthalmological fields, and provide an opthalmological composition having this minimum unit as an effective component. This invention provides an opthalmological composition, in particular, a corneal disorder treatment agent...

04/15/10 - 20100093642 - Novel polypeptides
The present invention relates to novel polypeptides, nucleic acids encoding said peptides, cell lines, vectors, pharmaceutical compositions and antibodies. The invention may be used to treat fungus, infections, ulcers, wounds, cancer and/or inflammation in a patient in need thereof....

04/08/10 - 20100087381 - Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
The present invention relates to a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders or diseases) of the gastrointestinal system. The method comprises administering to a subject in need thereof a therapeutically effective amount of...

04/01/10 - 20100081624 - Selective peptides that inhibit the biological activity of calcineurin
The invention relates to the biotechnology sector involving the area of human health. More specifically, the invention is based on the surprising usefulness of peptides LxVPc1, c3 and c4 as efficient selective inhibitors of the calcineurin signalling pathway (CN)-NFAT and the phosphate activity of CN. Said compounds are useful immunosuppressors...

02/11/10 - 20100035824 - Synergistic pharmaceutical composition
The invention relates to pharmaceutical compositions containing an isoflavone or isoflavone glycoside or a pharmaceutically acceptable salt or solvate of said isoflavone or isoflavone glycoside as an active substance. Also disclosed are uses of such pharmaceutical compositions....

02/04/10 - 20100029574 - Cosmetic compositions
The present invention generally features novel cosmetic skin and hair care compositions for enhancing the appearance of eyelashes and eyebrows. Specifically, the topical skin and hair care compositions of the invention contain a concentration of at least one of pentapeptide-17 tetrapeptide-12 that provide for thicker, longer and more voluminous appearing...

12/17/09 - 20090312266 - Peptide derived from vascular endothelial growth factor receptor-1 binding integrin alpha5beta1 having proangiogenic activity
Description of a sequence peptide isolated in the domain II type-immunoglobulin (Type-Ig) of the Vascular Endothelial Growth Factor receptor 1 (VEGF-1) binding integrin α5β1, usable for the preparation of pharmacological agents having proangiogenic activity....

12/17/09 - 20090312267 - Antifungal paints and coatings
Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building...

12/17/09 - 20090312268 - Antifungal paints and coatings
Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building...

12/17/09 - 20090312269 - Antifungal paints and coatings
Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building...

11/26/09 - 20090291901 - Control of radiation injury
The invention relates to the field of drug development against acute radiation injury caused by exposure to high-energy electromagnetic waves (X-rays, gamma rays) or particles (alpha particles, beta particles, neutrons). To date, there is no effective drug to ameliorate radiation injury after accidental exposure to ionizing irradiation. The invention provides...

11/19/09 - 20090286747 - Mntf peptide compositions and methods of use
The present invention relates to novel Motoneuronotrophic Factors (MNTF) peptides and analogs thereof, including compositions capable of promoting the growth and viability of neurons. MNTF peptides between two and six amino acids in length are provided, as well as analogs of these MNTF peptides that are modified by covalent attachment...

11/19/09 - 20090286748 - Anti-inflammatory compounds and uses thereof
The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-κB-dependent target gene expression in a cell....

10/15/09 - 20090258834 - Plasma protein-binding ligands
The invention provides an isolated or purified peptide that binds at least one plasma protein. In one embodiment, the isolated or purified peptide binds to fibrinogen, comprises no more than 10 amino acids, and comprises an amino acid sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5, an amino acid sequence Gly-Xaa6-Arg-Xaa7, or an amino acid sequence...

10/08/09 - 20090253639 - Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopeptidases
The present invention relates to modified opiorphin peptides as new inhibitors of metallo-ectopeptidases....

09/10/09 - 20090227518 - Compositions and methods for treating actin-mediated medical conditions
The present invention provides a method for treating a subject an actin-mediated medical condition by administering to the subject an actin modulator. In some embodiments, the actin-mediated medical condition is an intracellular actin-mediated medical condition. In other embodiments, the actin-mediated medical condition is a cellular-surface actin mediated medical condition....

09/10/09 - 20090227519 - Compounds for control of appetite
This invention relates generally to neuropeptide Y (“NPY”) Y4 receptor agonists including pancreatic polypeptide (PP), analogs thereof, and peptide fragments of PP, e.g. PP(32-36), and analogs thereof to pharmaceutical compositions containing such Y4 receptor agonists, and to methods for treatment of mammals using the same. The NPY Y4 receptor agonists...

09/10/09 - 20090227520 - Treatment methods using peptides related to amyloid precursor protein
The invention provides a compound having formula X1-Arg-Xaa-Arg-X2 in which X1 and X2 are up to 30 amino acid residues and Xaa is an amino acid residue. A preferred compound is the tripeptide Arg-Glu-Arg which corresponds to amino acid residues 328 to 330 of human amyloid precursor protein. The invention...

09/03/09 - 20090221512 - Pharmaceutical composition containing ghrp-6 to prevent and eliminate fibrosis and other pathological deposits in tissues
The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms...

08/13/09 - 20090203626 - Pediatric amino acid solution for parenteral nutrition
The present invention relates to an amino acid solution for the parenteral nutrition of pediatric patients. The amino acid solution provides for an increased concentration of glutamine, tyrosine, cysteine and taurine, while the concentrations of phenylalanine and methionine is small. Glutamine and tyrosine are provided in the form of oligopeptides....

08/13/09 - 20090203627 - Specific binding sites in collagen for integrins and use thereof
The present invention identified a high affinity binding sequence in collagen type III for the collagen-binding integrin I domains. Provided herein are the methods used to characterize the sequence, the peptides comprising this novel sequence and the use of the peptides in enabling cell adhesion. Also provided herein are methods...

07/23/09 - 20090186826 - Cosmetic or dermopharmaceutical compositions of ceramides and polypeptides
Personal care products including cosmetics, grooming products and topical pharmaceutical products can be produced including a polypeptide of between 3 and 12 amino acids in length and a ceramide. These formulations are particularly useful in addressing wrinkles in human subjects and in particular facial skin and hands. Certain analogs and...

07/16/09 - 20090181900 - Novel peptides and methods for the treatment of inflammatory disease
The invention relates to an isolated peptides comprising at least the amino acid sequence YDRREY or a derivative thereof, nucleic acids encoding the peptides, pharmaceutical compositions and methods for modulating β7 integrin function, including methods for treatment of inflammatory disorders, antibodies directed to said peptides and methods for identification of...

06/25/09 - 20090163425 - Peptide inhibiting angiotensin converting enzyme
The invention provides a peptide having an activity of inhibiting angiotensin-converting enzyme (ACE), and a food and drink and/or a pharmaceutical composition containing the peptide....

06/25/09 - 20090163426 - Tissue specific prodrugs
The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific membrane antigen (PSMA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. PSMA is secreted by prostatic glandular cells. Upon cleavage of the prodrug by PSMA, the therapeutic...

06/04/09 - 20090143310 - Method of stimulating the motility of the gastrointestinal system using ipamorelin
The present invention provides a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders, diseases, conditions, or drug- or surgery-induced dysfunction) of the gastrointestinal system, by administering to the subject a ghrelin mimetic, or pharmaceutically acceptable...

05/28/09 - 20090137494 - Tumor-activated prodrug compounds and treatment
The compound (W-Z-M) according to the invention comprises a component (M) chosen from the group consisting of markers and therapeutic agents possessing an intracellular active site (A.S.), linked to a ligand (W-Z) comprising an arm (Z) linked to a terminal group (W), characterized in that the linkage between the arm...

05/21/09 - 20090131328 - Furin inhibitors
Inhibitors for the endoprotease furin are provided for the prevention, diagnosis, treatment, and study of human and animal pathologies, which involve furin activity. These pathologies include infections caused by bacteria and virus that exploit host furin activity. These pathologies also include diseases that involve the expression of host proproteins that...

05/21/09 - 20090131329 - Treatment for allograft rejection
Provided are methods of treating a mammal at risk for allograft rejection. The methods comprise treating the mammal with a compound that reduces an interaction between a CXC chemokine and a CXC receptor....

05/07/09 - 20090118197 - Immune-modulating peptide
Disclosed are peptides having SEQ ID NOs: 1 to 24 that induce superoxide generation by human monocytes or neutrophils; that induce an intracellular calcium increase by human peripheral blood monocytes or neutrophils; binds to formyl peptide receptor or formyl peptide receptor-like 1; that induce chemotactic migration of human monocytes or...

05/07/09 - 20090118198 - Novel peptide derivatives useful as antimicrobial agents for treating wounds
The invention relates to a compound having the general formula (I) R1—NH—CH[(CH2)n—NH—C(NH)—NH2]-CO—R2-A-R4; a pharmaceutical composition comprising said compound and use of said compound for the manufacturing of a medicament for the treatment of a disease such as a microbial disease and/or proliferation/stimulation of eukaryotic cells....